A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting

Therapeutic Drug Monitoring

Volumn 20, Issue 2, 1998, Pages 158-164

  Charpiat, Bruno ^a   Falconi, Isabelle ^a   Bréant, Valeutine ^a   Jelliffe, Roger W ^b   Sab, Jean M ^a   Ducerf, Christian ^a   Fourcade, Nadine ^a   Thomasson, Annick ^a   Baulieux, Jacques ^a  

^a CROIX ROUSSE HOSPITAL   (France)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cyclosporine; Liver transplant; NPEM; Population pharmacokinetic analysis

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ACCURACY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; BAYES THEOREM; CHILD; COHORT STUDIES; CYCLOSPORINE; FEMALE; FRANCE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LIVER TRANSPLANTATION; MALE; MATHEMATICAL COMPUTING; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; VITAL STATISTICS;

EID: 0031969433     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199804000-00005     Document Type: Article

References (48)

1. Kahan BD, Shaw LM, Holt TD, Grevel J, Johnston A. Consensus document: Hawk's Kay meeting on therapeutic drug monitoring of cyclosporin. Clin Chem 1990;36:1510-6.
2. Schroeder TJ, Sridhar N, Pesce AJ, Wesley Alexander J, Roy First M. Clinical correlations of cyclosporin-specific and non specific assays in stable renal transplants, acute rejection, and cyclosporin nephrotoxicity. Ther Drug Monit 1993;15:190-4.
3. Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporin: inter- and intra-individual variations and metabolic pathways. Transplant Proc 1990;22:1110-2.
4. Karlsson MO, Lindberg-Freijs A. Comparison of method to calculate cyclosporin A bioavailability from consecutive oral and intravenous doses. J Pharmacokin Biopharm 1990;18:293-311.
5. Awni WM. Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokinet 1992;23:428-48.
6. Grevel J. Optimisation of immunosuppressive therapy using pharmacokinetic principles. Clin Pharmacokinet 1992;23:380-90.
7. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24:472-95.
8. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996;30:107-40.
9. Grevel J, Napoly KL, Welsh MS, Atkinson NE, Kahan BD. Prediction of acute graft rejection in renal transplantation: the utility of cyclosporin blood concentrations. Pharm Res 1991;8:278-81.
10. Grevel J, Kahan BD. Area under the curve monitoring of cyclosporin therapy: the early post-transplant period. Ther Drug Monit 1991;13:89-95.
11. Lindholm A, Kahan BD. Influence of cyclosporin pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-18.
12. Kahan BD, Welsh M, Rutzky LP. Challenges in cyclosporin therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 1995;17:621-4.
13. Hoppu K, Koskimies O, Holmberg C, Hirvisalo EL. Pharmacokinetically determined cyclosporin dosage in young children. Pediatr Nephrol 1991;5:1-4.
14. Serre-Debeauvais F, Iliadis A, Tranchand B, et al. Bayesian estimation of cyclosporin clearance in bone marrow graft. Ther Drug Monit 1990;12:16-22.
15. Lemoine A, Azoulay D, Gries JM, et al. Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation. Transplantation 1993;56:1410-4.
16. Cooney GF, Heifets M, Bell A, Shaw LM, Libetti G. Utility of pretransplantation cyclosporin pharmacokinetic studies. Ther Drug Monit 1994;16:151-4.
17. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and and comparison with non-Bayesian methods. J Pharm Sci 1982;71:1344-8.
18. Jelliffe RW, Iglesias T, Hurst A, Foo K, Rodriguez J. Individualizing gentamicin dosage regimens: A comparative review of selected models, data fitting methods, and monitoring strategies. Clin Pharmacokinet 1991;21:461-78.
19. Maire PH, Jelliffe RW, Dumarest C, et al. Contrôle adaptatif optimal des posologies: expérience des aminosides en gériatrie. In: Venot A, Degoullet P, eds. Informatique et Médicaments. Paris: Springer-Verlag, 1989:154-69.
20. Destache CJ, Hillemen DE, Mohiuddin SJ, Lang PT. Predictive performance of Bayesian and nonlinear least-squares regression programs for lidocaine. Ther Drug Monit 1992;14:286-91.
21. Chrystyn H, Ellis JW, Mulley BA, Peake MD. The accuracy and stability of Bayesian theophylline predictions. Ther Drug Monit 1988;10:299-305.
22. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992;22:447-67.
23. Aarons L, Balant LP, Mentré F, et al. Population approaches in drug development: Report an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol 1994;46:389-91.
24. Grevel J, Prost KP, Kahan BD. Michaelis-Menten kinetics determine cyclosporin steady-state concentrations: a population analysis in kidney transplant patients. Clin Pharmacol Ther 1993;53: 651-60.
25. Mallet A, Mentré F, Steimer JL, Lokiec F. Non parametric maximum likelihood estimation for population pharmacokinetic, with application to cyclosporin. J Pharmacokin Biopharm 1988;3:311-27.
26. Sallas WM, Nedelman JR, Sheiner LB, Meligeni JA, Robinson WT. A nonlinear mixed-effects pharmacokinetic model comparing two formulations of cyclosporin in stable transplant patients. J Pharmacokin Biopharm 1995;23:495-514.
27. Whiting B, Niven AA, Kelman AW, Briggs JD. Improved therapeutic control of cyclosporin in renal transplantation. In: Decision Support for Patient Management: Measurement, Modeling and Control. London: British Medical Informatics Society, 1989:33-8.
28. Whiting B, Niven AA, Kelman AW, et al. Bayesian kinetic control strategy for cyclosporin in renal transplantation. In: d'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. NY: Plenum Press, 1991:171-6.
29. Anderson JE, Munday AS, Kelman AW, et al. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporin concentrations in renal allograft recipients, Ther Drug Monit 1994;16:160-5.
30. Aarons L, Balant LP, Mentré F, et al. Practical experience and issues in designing and performing population pharmacokinetic/ pharmacodynamic studies. Eur J Clin Pharmacol 1996;49:251-4.
31. Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30:81-93.
32. Shumitzky A. Nonparametric EM algorithms for estimating prior distributions. Applied Math and Comput 1991;45:141-57.
33. Mallet A. Maximum likelihood estimation method for random coefficient regression models. Biometrika 1986;73:645-56.
34. Bréant V, Charpiat B, Sab JM, Maire P, Jelliffe RW. How many patients and blood levels are necessary for population pharmacokinetic analysis? A study of a one compartment model applied to cyclosporin. Eur J Clin Pharmacol 1996;51:283-8.
35. Jelliffe RW, Schumitzky A, Van Guilder M. Nonpharmacokinetic factors affecting aminoglycoside therapeutic precision: a simulation study. Drug Invest 1992;4:20-9.
36. Antal EJ, Grasela TH, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials, III: Prospective data collection versus retrospective data assembly. Clin Pharmacol Ther 1989;46:552-9.
37. Zielman S, Lotterer E, Sussner M, Buchard JH, Bircher J. Individualized dosage of gentamicin: a programmed pocket calculator is useful only when applied properly. Ther Drug Monit 1992;14: 125-31.
38. Charpiat B, Bréant V, Pivot-Dumarest C, Maire P, Jelliffe RW. Prediction of future serum concentrations with Bayesian fitted models: results with data collected by nurses versus trained pharmacy residents. Ther Drug Monit 1994;16:166-73.
39. TDx Abbott System Assays. Manuel Analytique. Rungis cedex, France: Laboratoires ABBOTT, Division Diagnostic, XII-CYCLO-MONO-13.
40. Jelliffe RW, D'Argenio DZ, Schumitzky A, Hu L, Liu M. The USC*PACK PC programs for planning, monitoring and adjusting drug dosage regimens. Proceedings of the 23rd Annual Meeting of the Association for the Advancement of Medical Instrumentation, May 14-18. Washington, 1988:51 (available from the first author through a noncommercial license agreement from the University of Southern California).
41. Dodge WF, Jelliffe RW, Richardson CJ, Bellanger RA, Hokanson JA, Snodgrass WR. Population pharmacokinetic models: Measures of central tendency. Drug Invest J 993;5:206-11.
42. Sheiner LB, Beal LS. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
43. Charpiat B, Bréant V. Another suggestion for measuring predictive performance for aminoglycoside therapy: Proceedings of the MEDINFO'92 Satellite Open Conference on Estimation and Control of Patient Variability for Individualized Antibiotic Therapy. Int J Biomed Comput 1994;36:161-2.
44. Tredger JM, Grevel J, Naoumov N, et al. Cyclosporin pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. Eur J Clin Pharmacol 1991;40:513-9.
45. Tsang VT, Johnston A, Heritier F, Leaver N, Hodson ME, Yacoub M. Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis: Effects of pancreatic enzymes and ranitidine. Eur J Clin Pharmacol 1994;46:261-5.
46. Tan KKC, Trull AK, Hue KL, Best NG, Wallwork J, Higenbottam TW. Pharmacokinetics of cyclosporin in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther 1993;53:544-54.
47. Turgeon KD, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporin in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-8.
48. Morris RG. Target concentration strategy for cyclosporin monitoring. Clin Pharmacokinet 1997;32:175-9.